VICORE PHARMA HOLDING

Vicore is a clinical-stage pharmaceutical company focused on severe lung disease and related indications. The company currently has four development programs, VP01, VP02, VP03 and VP04. VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (IPF), pulmonary arterial hypertension and COVID-19. VP02 is a new formulation and delivery route of thalidomide and focuses on the underlying disease and the severe cough associated with IPF. VP03 includes the development of new AT2 receptor agonists. VP04 develops a clinically validated digital therapeutic for IPF patients... We are an innovative Swedish clinical-stage pharmaceutical company dedicated to creating life-changing treatments for severe lung diseases. Embedded in our approach is the determination to find solutions for conditions which have an enormous deleterious impact on patients and their families and to transform the lives of those affected... Vicore's vision is to remove the pain and suffering..

Also known as: Vicore, Vicore Pharma, Vicore Pharma Holding AB

Primary location: Stockholm Sweden